Cardiovascular Complications of COVID-19
Springer International Publishing (Verlag)
978-3-030-90064-9 (ISBN)
This book discusses the evidence behind the relationship between COVID-19 and heart disease based on emerging state-of-the-art data. The rapid and unexpected global spread of the COVID-19 has revealed proportional levels of cardiovascular and metabolic complications. A myriad of pathogenetic mechanisms has come to the surface. There is still much research required to define whether cardiovascular disease causes COVID-19 complications or that cardiovascular disease appears as a result of the infection and which mechanisms are responsible. With cardiovascular and metabolic diseases already at pandemic levels and expected to increase further, this book provides readers with an urgent and thorough analysis of this association.
Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes provides answers to the increasing numbers of questions related to heart disease in COVID-19, highlighting the association between these pandemics and including risk factors, mechanisms and how these may impact diverse patients populations. It describes how COVID-19 impacts older patients and those with metabolic illnesses such as obesity and diabetes mellitus, while providing an overview of the observed gender dichotomy among patients. It therefore represents an essential resource not only for all cardiovascular physicians but also for any healthcare professionals managing patients with these diseases or those exploring COVID-19.
lt;p>Dr. Umair Mallick is a consultant cardiologist with an international portfolio in academic and industrial clinical research. He has made significant contributions to science and the medical fields internationally by serving clinical and healthcare institutions, academia, the pharmaceutical industry, and actively engaging in multiple important research initiatives and collaborations globally.
His clinical expertise includes complex hypertension, heart failure, stroke, and cardiovascular disease prevention, and has a special interest in the older age population. He has held several positions as a clinician and clinical researcher in prestigious world-class academic, and healthcare institutions including the National Health Services (NHS) of the United Kingdom and Europe, as well as pharmaceutical industrial institutions. He has served as an advisor and member of panels for several national and international academic organizations, has peer-reviewed for highly ranking prestigious medical journals, and has published in the field of cardiology, metabolic diseases, and clinical trials.
Dr. Mallick has designed and led various initiatives for the improvement of the quality of care of patients, education programs and clinical care pathways, research protocols, and clinical guidelines. He has advanced level expertise in designing, conducting, and analysis of large international complex clinical trials, and epidemiological studies, and has served in key areas of the drug discovery process, including collaboration with ethics and regulatory bodies in the domain of clinical research.
At present, he is the Director at Heart Health and Research International (HHRI) Ltd and ad hoc consultant with NHS hospitals in the United Kingdom.
Epidemiology.- Virology Of COVID 19.- Clinical Features And Complications Of COVID 19.-Treatment Options In Covid 19.- Inflammation And COVID 19.- Renin Angiotensin System And COVID 19.- Pathogenetic Mechanisms In Non-Cardiovascular Complications.- Cytokines And Viral Damage In COVID 19.- Thrombosis In COVID 19.- Angiotensin Converting Enzyme 2 In COVID 19.- Regulatory Systems And COVID 19.- Miscellaneous Novel Mechanisms In COVID 19.- Myocardial Injury And Acute Coronary Syndromes In COVID 19.- Heart Failure, Hypertension And Arrhythmias In COVID 19.- Patients With Cardiometabolic Diseases And COVID 19.- Older Age And COVID 19.- Gender Dichotomy And COVID 19.- Quality Of Research In COVID 19.- Conclusion.
| Erscheinungsdatum | 12.02.2022 |
|---|---|
| Zusatzinfo | X, 414 p. 87 illus., 69 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 792 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie |
| Studium ► Querschnittsbereiche ► Epidemiologie / Med. Biometrie | |
| Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung | |
| Schlagworte | ACE2 inhibitors • Cardiac injury • Cardiovascular disease in COVID-19 • Covid-19 • Heart disease • inflammation |
| ISBN-10 | 3-030-90064-9 / 3030900649 |
| ISBN-13 | 978-3-030-90064-9 / 9783030900649 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
